Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106578 | 0.91 | — | — | |
| SCHEMBL22931329 | 0.70 | — | — | |
| SCHEMBL19558036 | 0.66 | — | — | |
| SCHEMBL369355 | 0.48 | — | — | |
| SCHEMBL895221 | 0.44 | — | — | |
| SCHEMBL11277497 | 0.44 | — | — | |
| SCHEMBL10017669 | 0.44 | — | — | |
| SCHEMBL1468768 | 0.43 | — | — | |
| P-Xylene SCHEMBL11770184 | 0.41 | ACHE (1.00) | — | |
| P-Xylene SCHEMBL460348 | 0.41 | ACHE (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773052-B2 | Enamine compound and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-10-03 | — | — | US | disclosed |
| US-11773052-B2 | Enamine compound and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-10-03 | — | — | US | disclosed |
| US-20200087245-A1 | ENAMINE COMPOUND AND USE THEREOF | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20170348681-A1 | ACTIVATION OF SUPPORTED OLEFIN METATHESIS CATALYSTS BY ORGANIC REDUCTANTS | ETH ZURICH (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3233274-A1 | ACTIVATION OF SUPPORTED OLEFIN METATHESIS CATALYSTS BY ORGANIC REDUCTANTS | ETH Zürich (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095061-A1 | ACTIVATION OF SUPPORTED OLEFIN METATHESIS CATALYSTS BY ORGANIC REDUCTANTS | ETH ZURICH (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087245-A1 | ENAMINE COMPOUND AND USE THEREOF | ENY2, AHR, PAH | GSK3A 4651/4885GSK3B 4593/4885MGLL 4128/4885 |
| US-11773052-B2 | Enamine compound and use thereof | ENY2, AHR, PAH | GSK3A 4651/4885GSK3B 4593/4885MGLL 4128/4885 |
| US-20170348681-A1 | ACTIVATION OF SUPPORTED OLEFIN METATHESIS CATALYSTS BY ORGANIC REDUCTANTS | MON2, MSMO1, SGMS2 | GSK3A 2323/4885GSK3B 2448/4885MGLL 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.